Monopar Therapeutics’ (MNPR) “Hold” Rating Reiterated at Jones Trading

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “hold” rating restated by equities researchers at Jones Trading in a research note issued on Wednesday,Benzinga reports.

Several other research firms have also recently weighed in on MNPR. Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Monopar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Monopar Therapeutics Stock Performance

Shares of NASDAQ:MNPR opened at $33.43 on Wednesday. The firm has a market cap of $203.99 million, a price-to-earnings ratio of -16.97 and a beta of 1.18. The firm has a fifty day moving average price of $38.52 and a 200 day moving average price of $24.54. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new position in Monopar Therapeutics during the fourth quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Monopar Therapeutics during the 4th quarter worth about $13,182,000. RA Capital Management L.P. purchased a new position in shares of Monopar Therapeutics during the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics in the 4th quarter worth about $2,861,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.